Abstract:Zaiyan Wang, 1 Yuan Zhang, 2 Xiaoning Li 3 1 Department of Pulmonary and Critical Care Medicine, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, 201318, People's Republic of China; 2 Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, People's Republic of China; 3 Department of Geriatric Medicine, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, 201318, People's Republic of China Correspondence: Xiaoning Li, Department of Geriatric Medicine, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, 201318, People's Republic of China, Email Yuan Zhang Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, 200433, People's Republic of China, Email Idiopathic pulmonary fibrosis (IPF) poses a formidable clinical challenge, characterized by the thickening of alveolar septa and the onset of pulmonary fibrosis. The pronounced activation of oxidative stress emerges as a pivotal hallmark of inflammation. Traditional application of exogenous antioxidants proves inadequate in addressing oxidative stress, necessitating exploration into strategies to augment their antioxidant efficacy. Exosomes, nano-sized extracellular vesicles harboring a diverse array of bioactive factors, present as promising carriers with the potential to meet this challenge. Recent attention has been directed towards the clinical applications of exosomes in IPF, fueling the impetus for this comprehensive review. We have compiled fresh insights into the role of exosomes in modulating oxidative stress in IPF and delved into their potential as carriers for regulating endogenous reactive oxygen species generation. This review endeavors to bridge the divide between exosome research and IPF, traversing from bedside to bench. Through the synthesis of recent findings, we propose exosomes as a novel and promising strategy for improving the outcomes of IPF therapy. Keywords: oxidative stress, idiopathic pulmonary fibrosis, exosomes, treatment Idiopathic pulmonary fibrosis (IPF) presents a complex and debilitating pulmonary pathology characterized by the unexplained scarring of lung tissue. 1 This chronic and progressive interstitial lung disease not only poses a significant threat to affected individuals but also imposes a substantial burden on global healthcare systems. 2 The insidious nature of IPF lies in its capacity to progressively diminish lung function, resulting in respiratory distress and compromised quality of life, particularly among individuals in their 50s and 60s. 3 As the aging global population and persistent environmental risk factors contribute to an increasing prevalence of respiratory-related health concerns, urgent research efforts are warranted to develop innovative therapeutic approaches to mitigate the impact of this epidemic. 4 The pathogenesis of IPF unfolds through an intricate cascade of events disrupting the delicate equilibrium of the lung's cellular microenvironment. 5 Commencing with recurrent injuries to the alveolar epithelium, the response triggers abnormal wound healing, initiating the involvement of oxidative stress as a pivotal factor in the disease's progression. 6 Characterized by an imbalance between the production of reactive oxygen species (ROS) and the body's counteracting mechanisms, oxidative stress plays a crucial role in instigating and perpetuating fibrotic processes within lung tissue. 7 Various sources contribute to ROS production, including environmental factors, inflammatory cells, and dysfunctional mitochondria, setting off a cascade that activates fibroblasts, the key contributors to tissue repair. 8 These activated fibroblasts perpetuate the fibrotic cascade, generating excessive collagen and other matrix components, leading to scar tissue formation and the gradual distortion of lung architecture. 9 Oxidative stress induces immune dysregulation, drawing immune cells into the inflamed and fibrotic lung milieu, while inflammation contributes to oxidative stress, establishing a self-sustaining loop that perpetuates lung tissue damage. 10 Oxidative stress's association with cellular senescence accelerates aging processes, further impairing cellular repair mechanisms, intensifying the cycle of injury and fibrosis. 11 Mitochondrial dysfunction, another consequence of oxidative stress, amplifies ROS production and disrupts cellular energy balance, impacting normal physiological functions. 12 In the context of IPF, the conventional application of e -Abstract Truncated-

Enhanced oxidative stress aggravates BLM-induced pulmonary fibrosis by promoting cellular senescence through enhancing NLRP3 activation

IL-10 deficiency aggravates cell senescence and accelerates BLM-induced pulmonary fibrosis in aged mice via PTEN/AKT/ERK pathway

Extracellular HSP90α Promotes Cellular Senescence by Modulating TGF ‐β Signaling in Pulmonary Fibrosis

Procyanidin C1 inhibits bleomycin-induced pulmonary fibrosis in mice by selective clearance of senescent myofibroblasts

SLC15A3 plays a crucial role in pulmonary fibrosis by regulating macrophage oxidative stress

Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells

Late Breaking Abstract - Loss of PTEN induces alveolar epithelial cell senescence resulting in lung fibrosis via activated NF-?B

FOXO4 peptide targets myofibroblast ameliorates bleomycin‐induced pulmonary fibrosis in mice through ECM‐receptor interaction pathway

A novel pulmonary fibrosis NOD/SCID murine model with natural aging

N-methyl-D-aspartate receptor blockers attenuate bleomycin-induced pulmonary fibrosis by inhibiting endogenous mesenchymal stem cells senescence

ROS-mediated lysosomal membrane permeabilization and autophagy inhibition regulate bleomycin-induced cellular senescence

Blockade of TREM-1 Alleviates Alveolar Epithelial Cell Senescence Through Nrf2-mediated Antioxidant Pathways in Pulmonary Fibrosis

Sohlh2 promotes pulmonary fibrosis via repression of p62/Keap1/Nrf2 mediated anti-oxidative signaling pathway

Loss of PTEN induces lung fibrosis via alveolar epithelial cell senescence depending on NF‐κB activation

ALKBH5 SUMOylation-mediated FBXW7 m6A modification regulates alveolar cells senescence during 1-nitropyrene-induced pulmonary fibrosis

Pentoxifylline Inhibits Pulmonary Fibrosis by Regulating Cellular Senescence in Mice

Ligustilide modulates oxidative stress, apoptosis, and immunity to avoid pathological damages in bleomycin induced pulmonary fibrosis rats via inactivating TLR4/MyD88/NF-KB P65

Interleukin-18 Promotes Fibroblast Senescence in Pulmonary Fibrosis Through Down-Regulating Klotho Expression.

Mitigation of Oxidative Stress in Idiopathic Pulmonary Fibrosis Through Exosome-Mediated Therapies

Environmental tobacco smoke exposure exaggerates bleomycin-induced collagen overexpression during pulmonary fibrogenesis

Nitazoxanide alleviates experimental pulmonary fibrosis by inhibiting the development of cellular senescence